Latest Olaparib Stories

2014-07-02 08:24:16

LONDON, July 2, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: AstraZeneca PLC - Product Pipeline Review - 2014 http://www.reportbuyer.com/computing_electronics/manufacturing/astrazeneca_plc_product_pipeline_review_2013.html AstraZeneca PLC - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'AstraZeneca PLC - Product Pipeline Review - 2014', provides an overview of the AstraZeneca PLC's pharmaceutical research and development focus....

2014-06-05 12:28:09

Two New Therapies Will Match Progression-Free Survival Improvements Required By Surveyed U.S. Payers for Formulary Inclusion, According to a New Report from Decision Resources Group BURLINGTON, Mass., June 5, 2014 /PRNewswire/ -- Decision Resources Group finds that in addition to an improvement in median overall survival (MOS), delayed disease progression is one of the greatest unmet needs in the first-line treatment of advanced ovarian cancer (CaO). MOS and disease progression are also key...

2014-05-16 12:27:57

RnRMarketResearch.com adds "Ovarian Cancer Therapeutics in Major Developed Markets to 2020 - Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies" to its store. DALLAS, May 16, 2014 /PRNewswire-iReach/ -- "Ovarian Cancer Therapeutics in Major Developed Markets to 2020 Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies". The current Ovarian cancer therapeutics market is dominated by the use of generics - predominately...

2014-05-07 23:00:23

ResearchMoz.us include new market research report "Ovarian Cancer Therapeutics to 2020" to its huge collection of research reports. Get Detail Report With TOC at http://www.researchmoz.us/ovarian-cancer-therapeutics-to-2020-late-stage-pipeline-focuses-on-improved-progression-free-survival-and-targeted-therapies-report.html. Albany, New York (PRWEB) May 08, 2014 Researchmoz presents this most up-to-date research on "Ovarian Cancer Therapeutics to 2020 - Late-Stage Pipeline...

2012-11-13 12:15:34

-PI3-kinase inhibitors sensitized tumors to PARP inhibitors. -Combination significantly prolonged progression-free survival in mouse model. The simultaneous inhibition of two separate and seemingly unrelated pathways could potentially provide an effective treatment for women with triple-negative breast cancer, according to results of two studies published in the November issue of Cancer Discovery, a journal of the American Association for Cancer Research. Triple-negative breast cancers...

2012-03-29 02:27:15

Researchers identify genetic markers of drug sensitivity in cancer cells In the largest study of its kind, researchers have profiled genetic changes in cancer with drug sensitivity in order to develop a personalised approach to cancer treatments. The team uncovered hundreds of associations between mutations in cancer genes and sensitivity to anticancer drugs. One of the key responses the team found was that cells from a childhood bone cancer, Ewing's sarcoma, respond to a drug that is...

2012-01-25 04:45:31

Among women with invasive epithelial ovarian cancer, patients having a germline (gene change in a reproductive cell that could be passed to offspring) mutation in the BRCA1 or BRCA2 genes was associated with improved 5-year overall survival, with BRCA2 carriers having the best prognosis, according to a study in the January 25 issue of JAMA. "Germline mutations in the tumor suppressor genes BRCA1 and BRCA2 are the strongest known genetic risk factors for both breast and epithelial ovarian...

2012-01-14 01:58:13

OHSU Knight Cancer Institute study results suggest that more patients than initially thought could potentially be treated with a new class of drugs, PARP inhibitors A constellation of defective proteins suspected in causing a malfunction in the body´s ability to repair its own DNA could be the link scientists need to prove a new class of drugs will be effective in treating a broad range of ovarian cancer patients, an Oregon Health & Science University Knight Cancer Institute study...

Word of the Day
  • A Roman unit of weight, 1⁄1728 of a pound.
  • A weight of four grains used in weighing gold and precious stones; a carat.
  • In anatomy, a formation suggesting a husk or pod.
  • The lowest unit in the Roman coinage, the twenty-fourth part of a solidus.
  • A coin of base silver of the Gothic and Lombard kings of Italy.
'Siliqua' comes from a Latin word meaning 'a pod.'